|

SEP-363856 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Ulotaront

Pipeline

Phase 3: 2

Top Sponsors

  • Otsuka Pharmaceutical Development & Commercialization, Inc.2

Indications

  • Generalized Anxiety Disorder2
  • Anxiety2

Redlands, California1 trial

A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder

Anderson Clinical Research

Phase 3

Jacksonville, Florida1 trial

A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder

Clinical Neuroscience Solutions, LLC

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.